Tradestie Institutional Equity Comparison Engine

TAK vs TEVA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TEVA Overall Edge

TEVA Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while TAK counters with relative strength in Valuation. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus TEVA at 14.2x Forward P/E and 19.9% operating margin (-1.9% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against TEVA sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TAK
TAK 12.7x vs TEVA 14.2x Fwd P/E
Growth & Margin Winner TEVA
Op Margin 16.6% vs 19.9% ยท YoY +6.7% vs -1.9%
Momentum & Technical Winner TEVA
1Y +51.8% vs +68.4% ยท 52W Pos 97% vs 92%
Options & Structure Winner TEVA
UNCLASSIFIED (5th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
TEVA NYSE
Teva Pharmaceutical Industries Limited American Depositary Shares
Pharmaceutical Preparations
$43.01
-3.35% 1D
Market Cap $51.1B
1M Return +3.64%
1Y Return +68.4%
Forward P/E 14.2x
Unified AI Score
29.8 / 100 SELL
Tech 50.0 Fund 29.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TAK +51.79% TEVA +68.4% Spread: +16.61 pp (TEVA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TAK TTM Op. Margin: 16.6% TEVA TTM Op. Margin: 19.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs TEVA. Trailing 12-month operating profitability (TAK 16.6% vs TEVA 19.9%) and valuation multiples (TAK 12.7x vs TEVA 14.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TAK (6) vs TEVA (4)
Institutional Metric TAK TEVA Criterion Row Winner
Market Capitalization Scale $67.5B $51.1B Larger Scale TAK
Trailing P/E Ratio Valuation N/M 101.8x Lower Multiple TEVA
Forward P/E Ratio Valuation 12.7x 14.2x Lower Multiple TAK
Revenue Growth (YoY) Growth +6.7% -1.9% Higher Growth TAK
Operating Margin (TTM) Profitability 16.6% 19.9% Higher Margin TEVA
Net Profit Margin Profitability 0.9% 2.9% Higher Margin TEVA
Return on Equity (ROE) Capital Efficiency 0.6% 6.7% Higher ROE TEVA
52-Week Range Position Momentum 97% ($14โ€“$22) 92% ($24โ€“$45) Stronger Trend TAK
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 22% Vol 0.51ฮฒ ยท 29% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 47.7 / 100 (HOLD) 29.8 / 100 (SELL) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TAK vs TEVA Buy Guide
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TEVA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live TEVA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TAK nor TEVA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.